Literature DB >> 6444543

On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice.

J A Houghton, P J Houghton.   

Abstract

Three fluorinated pyrimidines, 5-fluorouracil (FUra), 5-fluorouridine (FUrd), and 5-fluoro-2'-dexoyuridine (FdUrd), have been studied in four human colonic tumor xenograft lines. The preliminary findings may be summarized as follows: 1) after equimolar dosages, the agent reaching the highest concentration in the tumor produced the highest level of fluorodeoxyuridylate (FdUMP); 2) within a tumor line, the order of response to the three agents is related to the order of FdUMP-generation; 3) the tumor-response did not correspond to the level of analogue-incorporation into RNA; 4) the measurement of levels of free FdUMP in tumors is a poor prognostic indicator of drug-response; and 5) the levels of FdUMP in the tumors are maintained for considerable periods and appear to be dependent upon the maintenance of the levels of either FUra or FUrd, irrespective of the parent agent administered.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6444543     DOI: 10.1002/1097-0142(19800315)45:5+<1159::aid-cncr2820451320>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor.

Authors:  P A Clavien; M Selzner; M A Morse
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

2.  Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma.

Authors:  P Dias; D M Parham; D N Shapiro; B L Webber; P J Houghton
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

Review 3.  Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.

Authors:  P J Houghton; J A Houghton; B J Hazelton; S Radparvar
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

4.  The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.

Authors:  S Kase; T Kubota; M Watanabe; T Takahara; T Takeuchi; H Yamaguchi; T Furukawa; T Teramoto; S Kodaira; K Ishibiki
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.

Authors:  P J Houghton; P J Cheshire; L Myers; C F Stewart; T W Synold; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.

Authors:  P J Houghton; P J Cheshire; J C Hallman; J L Gross; R J McRipley; J H Sun; C H Behrens; D L Dexter; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.

Authors:  P J Houghton; P J Cheshire; J D Hallman; L Lutz; H S Friedman; M K Danks; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 8.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

9.  Kinetic analysis of 5-fluorouracil action against various cancer cells.

Authors:  M Inaba; J Mitsuhashi; S Ozawa
Journal:  Jpn J Cancer Res       Date:  1990-10

10.  Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.

Authors:  B J Braakhuis; E J Schoevers; E C Heinerman; G Sneeuwloper; G B Snow
Journal:  Br J Cancer       Date:  1983-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.